U.S. Supreme Court Denies Review Of Design Defect Claim In Metoclopramide Case

WASHINGTON, D.C. - The U.S. Supreme Court on Oct. 7 denied review of a plaintiff's claim that her design defect claim involving the heartburn drug metoclopramide is not preempted (Julie Demahy v. Schwartz Pharma, Inc., et al., No. 12-1093, U.S. Sup.).

Access this news story on lexis.com®